SpaceX Drops 6% in Premarket After Morgan Stanley Lifts Target to $300

SpaceX shares fell sharply in premarket trading after Morgan Stanley increased its price target to $300, according to The Coin Republic. The stock was quoted at $131.55 at 9:12 a.m., a decline of $9.76, or 6.9%, from the previous close of $141.31. The report also noted that the target implied roughly 114% upside when measured against a $140 share price. The target increase did not translate into positive near-term trading. At the quoted premarket level, SpaceX was $9.44 below the $140 valuation used to describe the target’s implied upside and $19.55 below the previous close. The available coverage described a premarket move rather than a confirmed regular-session close, making $141.31 the reference point for the reported decline.

Although The Coin Republic and The Cryptonomist were both listed among the outlets, their summaries do not provide matching coverage of the SpaceX development. The Coin Republic supplies the SpaceX price, Morgan Stanley target and implied-upside figures, while The Cryptonomist’s summary focuses on Rheinmetall’s position below major exponential averages and neutral-to-bearish daily momentum. It adds no independent evidence concerning SpaceX.

The development concerns private aerospace company SpaceX rather than a cryptocurrency asset, so no coin-specific move applies. The broader crypto market was broadly positive, with total capitalization at $2.73 trillion and Bitcoin up 1.65% over 24 hours. The Fear & Greed index stood at 50, classified as Neutral, indicating neither strong sentiment toward risk nor pronounced caution based on the supplied reading.

For SpaceX shareholders, the immediate tension is between a more bullish analyst target and the direction of shares during premarket trading. The $300 target, the $140 reference price and the $141.31 previous close provide the principal benchmarks for assessing whether the early decline persists once broader market trading begins. The supplied figures do not identify why investors sold the shares despite the target increase or provide details about Morgan Stanley’s underlying analysis.